Literature DB >> 33148489

The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease.

Rachel A Caston1, Silpa Gampala1, Lee Armstrong1, Richard A Messmann2, Melissa L Fishel3, Mark R Kelley4.   

Abstract

Apurinic/apyrimidinic (AP) endonuclease-reduction/oxidation factor 1 (APE1/Ref-1, also called APE1) is a multifunctional enzyme with crucial roles in DNA repair and reduction/oxidation (redox) signaling. APE1 was originally described as an endonuclease in the Base Excision Repair (BER) pathway. Further study revealed it to be a redox signaling hub regulating critical transcription factors (TFs). Although a significant amount of focus has been on the role of APE1 in cancer, recent findings support APE1 as a target in other indications, including ocular diseases [diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD)], inflammatory bowel disease (IBD) and others, where APE1 regulation of crucial TFs impacts important pathways in these diseases. The central responsibilities of APE1 in DNA repair and redox signaling make it an attractive therapeutic target for cancer and other diseases.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33148489      PMCID: PMC7855940          DOI: 10.1016/j.drudis.2020.10.015

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  98 in total

1.  Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization.

Authors:  Sheik Pran Babu Sardar Pasha; Kamakshi Sishtla; Rania S Sulaiman; Bomina Park; Trupti Shetty; Fenil Shah; Melissa L Fishel; James H Wikel; Mark R Kelley; Timothy W Corson
Journal:  J Pharmacol Exp Ther       Date:  2018-08-03       Impact factor: 4.030

2.  Design and activity of AP endonuclease-1 inhibitors.

Authors:  Zhiwei Feng; Stanton Kochanek; David Close; LiRong Wang; Ajay Srinivasan; Abdulrahman A Almehizia; Prema Iyer; Xiang-Qun Xie; Paul A Johnston; Barry Gold
Journal:  J Chem Biol       Date:  2015-04-19

3.  Effects of APE1 Asp148Glu polymorphisms on OPMD malignant transformation, and on susceptibility to and overall survival of oral cancer in Taiwan.

Authors:  Hsin-I Huang; Chung-Ho Chen; Sheng-Hung Wang; Li-Hsuan Wang; Ying-Chu Lin
Journal:  Head Neck       Date:  2019-01-16       Impact factor: 3.147

4.  Acetylation on critical lysine residues of Apurinic/apyrimidinic endonuclease 1 (APE1) in triple negative breast cancers.

Authors:  Mattia Poletto; Carla Di Loreto; Daniela Marasco; Elena Poletto; Fabio Puglisi; Giuseppe Damante; Gianluca Tell
Journal:  Biochem Biophys Res Commun       Date:  2012-06-16       Impact factor: 3.575

Review 5.  Biological and clinical consequences of NPM1 mutations in AML.

Authors:  E M Heath; S M Chan; M D Minden; T Murphy; L I Shlush; A D Schimmer
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

6.  Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors.

Authors:  Zahrah Zawahir; Raveendra Dayam; Jinxia Deng; Cherelene Pereira; Nouri Neamati
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

7.  Endonuclease and redox activities of human apurinic/apyrimidinic endonuclease 1 have distinctive and essential functions in IgA class switch recombination.

Authors:  Barbara Frossi; Giulia Antoniali; Kefei Yu; Nahid Akhtar; Mark H Kaplan; Mark R Kelley; Gianluca Tell; Carlo E M Pucillo
Journal:  J Biol Chem       Date:  2019-01-31       Impact factor: 5.157

8.  RNA under attack: cellular handling of RNA damage.

Authors:  Elisabeth J Wurtmann; Sandra L Wolin
Journal:  Crit Rev Biochem Mol Biol       Date:  2009 Jan-Feb       Impact factor: 8.250

9.  Uncoupling of the base excision and nucleotide incision repair pathways reveals their respective biological roles.

Authors:  Alexander A Ishchenko; Eric Deprez; Andrei Maksimenko; Jean-Claude Brochon; Patrick Tauc; Murat K Saparbaev
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-10       Impact factor: 11.205

10.  Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.

Authors:  Juliana C Santos; Alexandre Funck; Isabelle J L Silva-Fernandes; Silvia H B Rabenhorst; Carlos A R Martinez; Marcelo L Ribeiro
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

View more
  13 in total

1.  Binding of AP endonuclease-1 to G-quadruplex DNA depends on the N-terminal domain, Mg2+ and ionic strength.

Authors:  Aaron M Fleming; Shereen A Howpay Manage; Cynthia J Burrows
Journal:  ACS Bio Med Chem Au       Date:  2021-10-29

2.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

3.  Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of Human Melanoma.

Authors:  Razan Alhazmi; Shirley Tong; Shaban Darwish; Elina Khanjani; Bharti Khungar; Swati Chawla; Zhonghui Zheng; Richard Chamberlin; Keykavous Parang; Sun Yang
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.927

4.  APE1/Ref-1 - One Target with Multiple Indications: Emerging Aspects and New Directions.

Authors:  Mahmut Mijit; Rachel Caston; Silpa Gampala; Melissa L Fishel; Jill Fehrenbacher; Mark R Kelley
Journal:  J Cell Signal       Date:  2021

5.  Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target.

Authors:  Silpa Gampala; Fenil Shah; Xiaoyu Lu; Hye-Ran Moon; Olivia Babb; Nikkitha Umesh Ganesh; George Sandusky; Emily Hulsey; Lee Armstrong; Amber L Mosely; Bumsoo Han; Mircea Ivan; Jing-Ruey Joanna Yeh; Mark R Kelley; Chi Zhang; Melissa L Fishel
Journal:  J Exp Clin Cancer Res       Date:  2021-08-10

6.  Bioorthogonal regulation of DNA circuits for smart intracellular microRNA imaging.

Authors:  Yingying Chen; Xue Gong; Yuhui Gao; Yu Shang; Jinhua Shang; Shanshan Yu; Ruomeng Li; Shizhen He; Xiaoqing Liu; Fuan Wang
Journal:  Chem Sci       Date:  2021-11-08       Impact factor: 9.825

Review 7.  Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.

Authors:  May Elbanna; Nayela N Chowdhury; Ryan Rhome; Melissa L Fishel
Journal:  Front Oncol       Date:  2021-10-18       Impact factor: 6.244

8.  RelA Is an Essential Target for Enhancing Cellular Responses to the DNA Repair/Ref-1 Redox Signaling Protein and Restoring Perturbated Cellular Redox Homeostasis in Mouse PDAC Cells.

Authors:  Mahmut Mijit; Randall Wireman; Lee Armstrong; Silpa Gampala; Zonera Hassan; Christian Schneeweis; Guenter Schneider; Chi Zhang; Melissa L Fishel; Mark R Kelley
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

Review 9.  DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.

Authors:  Ruixue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-09

10.  APE1/Ref-1 as a Novel Target for Retinal Diseases.

Authors:  Curtis Heisel; Jonah Yousif; Mahmut Mijiti; Kostas Charizanis; Mitchel Brigell; Timothy W Corson; Mark R Kelley
Journal:  J Cell Signal       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.